Company news
OpSens Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Haemonetics completes acquisition of OpSens
December 12, 2023
OpSens receives final order for arrangement with haemonetics
December 8, 2023
OpSens' shareholders approve arrangement with haemonetics
December 1, 2023
OpSens obtains regulatory clearance of arrangement in the united states and Canada; regulatory approvals condition satisfied
November 28, 2023
OpSens announces fourth quarter and fiscal year 2023 Financial results
November 22, 2023
Independent proxy advisory firm ISS recommends shareholders vote "for" OpSens Inc. plan of arrangement with haemonetics corporation
November 13, 2023
OpSens receives interim order and files management information circular in connection with special meeting of shareholders
November 2, 2023
OpSens announces the positive clinical results from the SAFE-TAVI study with SavvyWire in europe
October 23, 2023
OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in San Francisco October 23 - 26, 2023
October 17, 2023
OpSens signs definitive agreement for its acquisition by haemonetics
October 10, 2023
OpSens announces a third consecutive quarter of record revenues for third quarter fiscal 2023
July 13, 2023
OpSens to host third quarter fiscal year 2023 financial results conference call on Thursday July 13, 2023
July 6, 2023
OpSens announces inclusion of SavvyWire(tm) in complete TAVR study
May 10, 2023
OpSens Announces Participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference
April 20, 2023
OpSens announces record revenue for second quarter fiscal 2023
April 13, 2023
OpSens announces completion of enrollment in SAFE-TAVI study with SavvyWire® in Europe
April 11, 2023
OpSens to host second quarter fiscal year 2023 financial results conference call on Thursday April 13, 2023
April 6, 2023
OpSens announces 1,000th SavvyWire procedure
April 5, 2023
OpSens appoints John Hannigan as Chief Financial Officer
March 27, 2023
OpSens awarded interventional specialty diagnostics agreement with Premier for SavvyWire(tm)
March 14, 2023
OpSens announces SavvyWire(tm) used during two live cases at CRT conference
February 28, 2023
OpSens Reports Annual General and Special Shareholders Meeting Voting Results
January 25, 2023
OpSens to participate in the lytham partners investor select conference
January 25, 2023
OpSens announces record first quarter fiscal 2023 Financial results
January 12, 2023
OpSens to host first quarter fiscal year 2023 financial results conference call on Thursday January 12, 2023
January 5, 2023
OpSens announces filing of preliminary base shelf prospectus
December 22, 2022
OpSens announces closing of $11.5 million bought deal public offering including $1.5 million over-allotment option exercised in full
December 22, 2022
OpSens Inc. announces $10 million bought deal offering
December 1, 2022
OpSens announces first SavvyWire(tm) procedure in New Zealand
November 29, 2022
OpSens announces fourth quarter and fiscal year 2022 Financial results
November 22, 2022
OpSens to host fourth quarter fiscal year 2022 financial results conference call and year-end update on November 22, 2022
November 16, 2022
OpSens announces departure of CFO
November 1, 2022
OpSens announces first SavvyWire clinical cases in Europe and launch of SAFE-TAVI study
October 26, 2022
OpSens announces first SavvyWire procedure in the United States by Dr. Philippe Genereux of Morristown Medical Center
September 23, 2022
OpSens announces FDA clearance for the SavvyWire(tm) for use in transcatheter aortic valve replacement (TAVR) procedures
September 15, 2022
OpSens to Participate in the Transcatheter Cardiovascular Therapeutics Conference (TCT) in Boston September 16-19, 2022
September 14, 2022
OpSens announces third quarter fiscal 2022 financial results with record quarterly revenues
July 14, 2022
OpSens Awarded Interventional Specialty Diagnostics Agreement with Premier for OptoWire III
July 11, 2022
OpSens to host third quarter fiscal year 2022 financial results conference call on Thursday, July 14
July 7, 2022
OpSens announces global SavvyWire(tm) first commercial use
June 7, 2022
OpSens SavvyWire(tm) first-in-human results presented at europcr in paris and simultaneously published in eurointervention journal
May 19, 2022
OpSens announces publication in jscai of data supporting the correlation between the OptoWire and a novel TAVR interface with standard of care, before and after TAVR
May 18, 2022
OpSens announces Health Canada approval for its new TAVR guidewire
April 26, 2022
OpSens announces second quarter fiscal 2022 Financial results
April 13, 2022
OpSens to host second quarter fiscal year 2022 financial results conference call on Wednesday, April 13
April 6, 2022
OpSens to Participate in the 32nd Annual Oppenheimer Healthcare Conference March 15th to 17th
March 14, 2022
OpSens Reports on Voting Results from its Annual Shareholders Meeting
February 25, 2022
OpSens appoints Brad Davis as new chief commercial officer
February 9, 2022
OpSens announces abiomed 4-year supply agreement extension to 2028
February 1, 2022
OpSens named to 2022 OTCQX Best 50
January 24, 2022
Decks
The 5 newest of 12 decks. Every deck is listed under its year.
- Investor Presentation (November 2023)
Investor deck · 48 slides · Nov 22, 2023
- Investor Presentation (July 2023)
Investor deck · 48 slides · Jul 31, 2023
- Investor Presentation (July 2023)
Investor deck · 44 slides · Jul 31, 2023
- Investor Presentation (May 2023)
Investor deck · 48 slides · May 31, 2023
- Investor Presentation (2023)
Investor deck · 44 slides · Mar 1, 2023